Welireg Filmtabl,90St x 40mg(belzutifan)

Reference priceJPY ¥91,875.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.

Brand	Welireg
Manufacturer	MSD Merck Sharp & Dohme AG
Prescription required	Yes

Description

Welireg Filmtabl,90St x 40mg(belzutifan) is a medicine catalog record in the MediPriceHub database. Active ingredient: belzutifan. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: MSD Merck Sharp & Dohme AG. Therapeutic category: Medicine Library > Oncology Medicines > Oncology Other Drugs. Pack information: 40, 90. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.

Benefits

WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease Renal Cell Carcinoma with a Clear Cell Component (ccRCC) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the adjuvant treatment of adult patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. as monotherapy, for treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

How to Use

Use belzutifan under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.

Specification

Active ingredient: belzutifan. Pack size: 40, 90. Pack unit: bottle. Manufacturer: MSD Merck Sharp & Dohme AG. Origin country: Switzerland. Source category: Medicine Library > Oncology Medicines > Oncology Other Drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.

Side Effects

Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.

この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。